Baxter International (NYSE:BAX) Price Target Lowered to $15.00 at Morgan Stanley

Baxter International (NYSE:BAX) had its price target reduced by Morgan Stanley from $19.00 to $15.00 in a report released on Tuesday, MarketBeat reports. They currently have an underweight rating on the medical instruments supplier’s stock.

Several other brokerages have also recently issued reports on BAX. UBS Group dropped their target price on Baxter International from $24.00 to $21.00 and set a “neutral” rating on the stock in a research report on Friday, October 31st. The Goldman Sachs Group dropped their price objective on Baxter International from $25.00 to $22.00 and set a “neutral” rating on the stock in a research report on Friday, October 31st. Jefferies Financial Group lowered their price target on shares of Baxter International from $25.00 to $21.00 and set a “hold” rating on the stock in a report on Thursday, October 30th. Barclays cut their price objective on shares of Baxter International from $41.00 to $36.00 and set an “overweight” rating on the stock in a research report on Monday, August 4th. Finally, Zacks Research cut shares of Baxter International from a “hold” rating to a “strong sell” rating in a research report on Friday, October 31st. Two research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Reduce” and an average price target of $22.50.

Baxter International Trading Down 1.2%

Baxter International stock opened at $18.86 on Tuesday. Baxter International has a 1 year low of $17.40 and a 1 year high of $37.74. The firm’s 50 day moving average price is $20.65 and its 200-day moving average price is $24.97. The company has a debt-to-equity ratio of 1.21, a current ratio of 1.84 and a quick ratio of 1.18. The stock has a market cap of $9.69 billion, a P/E ratio of -28.57, a PEG ratio of 1.09 and a beta of 0.61.

Baxter International (NYSE:BAX) last posted its earnings results on Thursday, October 30th. The medical instruments supplier reported $0.69 earnings per share for the quarter, topping analysts’ consensus estimates of $0.60 by $0.09. Baxter International had a negative net margin of 3.09% and a positive return on equity of 17.38%. The firm had revenue of $2.84 billion for the quarter, compared to the consensus estimate of $2.88 billion. During the same period in the previous year, the firm posted $0.80 EPS. The business’s quarterly revenue was up 5.0% on a year-over-year basis. Baxter International has set its Q4 2025 guidance at 0.520-0.570 EPS and its FY 2025 guidance at 2.350-2.400 EPS. On average, equities analysts predict that Baxter International will post 2.48 earnings per share for the current fiscal year.

Baxter International Cuts Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, January 2nd. Investors of record on Friday, November 28th will be paid a dividend of $0.01 per share. The ex-dividend date is Friday, November 28th. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.2%. Baxter International’s payout ratio is presently -6.06%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Zions Bancorporation National Association UT acquired a new position in Baxter International in the 1st quarter valued at about $27,000. CoreFirst Bank & Trust purchased a new position in shares of Baxter International in the 2nd quarter valued at approximately $27,000. Imprint Wealth LLC purchased a new position in shares of Baxter International in the 3rd quarter valued at approximately $27,000. Creative Financial Designs Inc. ADV increased its holdings in shares of Baxter International by 169.6% in the second quarter. Creative Financial Designs Inc. ADV now owns 984 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 619 shares during the period. Finally, MTM Investment Management LLC purchased a new stake in shares of Baxter International during the second quarter worth approximately $30,000. 90.19% of the stock is owned by hedge funds and other institutional investors.

About Baxter International

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.